Health AI Central
Share:
Peer-Reviewed Publication
Cancer Gene Ther2025;32(6):649-661.June 1, 2025Journal Article

Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.

Tatiana V Kudling1, Dmitrii Bychkov2, James H A Clubb1,3, Santeri A Pakola1, Victor Arias1, Elise Jirovec1, Mirte van der Heijden1, Nea Ojala1, Dafne C A Quixabeira1,3, Lyna Haybout1,3, Katriina J Jalkanen4, Tuomo Alanko5, Riikka Havunen3, Suvi Sorsa3, Claudia Kistler3, Anna Kanerva1,6, Otto Hemminki1,7, Joao M Santos1,3, Victor Cervera-Carrascon1,3, Akseli Hemminki8,9,10
1Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
2Digital Diagnostics Group, Institute for Molecular Medicine Finland (FIMM), Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
3TILT Biotherapeutics Ltd, Helsinki, Finland.
4Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.
5Docrates Cancer Center, Helsinki, Finland.
6Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
7Department of Urology, Helsinki University Hospital, Helsinki, Finland.
8Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.
9TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.
10Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland. akseli.hemminki@helsinki.fi.
PubMed PMC DOI PDF

Abstract

Oncolytic adenovirus Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123, igrelimogene litadenorepvec) shows promise as a therapeutic agent capable of causing tumor regression and activating host immunity. A phase I clinical study TUNIMO (NCT04695327) assessed its safety as monotherapy in patients with various solid tumors. Through single-cell profiling of peripheral blood, we identified distinct immunologica…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.